Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02966782
Registration number
NCT02966782
Ethics application status
Date submitted
15/11/2016
Date registered
17/11/2016
Date last updated
9/05/2023
Titles & IDs
Public title
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
Query!
Scientific title
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
Query!
Secondary ID [1]
0
0
2016-001904-46
Query!
Secondary ID [2]
0
0
M15-522
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myelodysplastic Syndromes (MDS)
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - venetoclax
Treatment: Drugs - azacitidine
Experimental: Venetoclax monotherapy (Cohort 1) -
Experimental: Venetoclax + azacitidine (Cohort 2) -
Experimental: Safety Expansion (Cohort 3) -
Treatment: Drugs: venetoclax
Tablet
Treatment: Drugs: azacitidine
Powder for injection, subcutaneously or intravenous
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
AUCt for azacitidine
Query!
Assessment method [1]
0
0
Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for azacitidine
Query!
Timepoint [1]
0
0
Up to 32 days
Query!
Primary outcome [2]
0
0
Clearance (CL) for azacitidine
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 32 days
Query!
Primary outcome [3]
0
0
Cmax for azacitidine
Query!
Assessment method [3]
0
0
Maximum plasma concentration (Cmax) of azacitidine
Query!
Timepoint [3]
0
0
Up to 32 days
Query!
Primary outcome [4]
0
0
Tmax for venetoclax
Query!
Assessment method [4]
0
0
Time to Cmax (peak time, Tmax) for venetoclax
Query!
Timepoint [4]
0
0
Up to 32 days
Query!
Primary outcome [5]
0
0
Recommended Phase 2 Dose (RPTD) and dosing schedules of venetoclax as monotherapy and in combination with azacitidine
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Measured from Day 1 until day 28 per dose level.
Query!
Primary outcome [6]
0
0
AUC[0 to infinity] for azacitidine
Query!
Assessment method [6]
0
0
Area under the plasma concentration-time curve from Time 0 to infinite time.
Query!
Timepoint [6]
0
0
Up to 32 days
Query!
Primary outcome [7]
0
0
Tmax for azacitidine
Query!
Assessment method [7]
0
0
Time to Cmax (peak time, Tmax) for azacitidine
Query!
Timepoint [7]
0
0
Up to 32 days
Query!
Primary outcome [8]
0
0
AUC [0-24] for venetoclax
Query!
Assessment method [8]
0
0
AUC over a 24-hour dose interval (AUC[0-24]) for venetoclax
Query!
Timepoint [8]
0
0
Up to 32 days
Query!
Primary outcome [9]
0
0
AUCt for venetoclax
Query!
Assessment method [9]
0
0
Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for venetoclax
Query!
Timepoint [9]
0
0
Up to 32 days
Query!
Primary outcome [10]
0
0
Cmax of venetoclax
Query!
Assessment method [10]
0
0
Maximum plasma concentration (Cmax) of venetoclax
Query!
Timepoint [10]
0
0
Up to 32 days
Query!
Primary outcome [11]
0
0
Half-life (t[1/2]) for azacitidine
Query!
Assessment method [11]
0
0
Terminal elimination half-life (t[1/2]) for azacitidine
Query!
Timepoint [11]
0
0
Up to 32 days
Query!
Primary outcome [12]
0
0
Number of Participants With Adverse Events (AEs)
Query!
Assessment method [12]
0
0
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Query!
Timepoint [12]
0
0
Up to Maximum of 24 months
Query!
Secondary outcome [1]
0
0
Event-Free Survival (EFS)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Measured from the date of the first dose of study drug to date of earliest disease progression, death, or initiation of new non-protocol-specified anti-MDS therapy without documented progression, and for up to 5 years after the last subject is enrolled.
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Measured from the date of first dose of study drug to the date of death, and for up to 5 years after the last subject is enrolled.
Query!
Secondary outcome [3]
0
0
Rate of Modified Overall Response (mORR)
Query!
Assessment method [3]
0
0
Proportion of participants with a mORR using best outcome will be calculated.
Query!
Timepoint [3]
0
0
Measured from Cycle 1 Day 1 (C1D1) as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [4]
0
0
Time to next treatment (TTNT)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Measured from first dose of study drug to start of new non-protocol specified MDS therapy, and for up to 5 years after the last subject is enrolled.
Query!
Secondary outcome [5]
0
0
Duration of mORR
Query!
Assessment method [5]
0
0
Defined as the number of days from the date of first response (CR, mCR or PR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier..
Query!
Timepoint [5]
0
0
Measured from the date of first response (CR, mCR or PR) to the earliest documentation of progressive disease (PD), and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [6]
0
0
Rate of platelet (PLT) transfusion independence
Query!
Assessment method [6]
0
0
Proportion of participants who become platelet transfusion-independent
Query!
Timepoint [6]
0
0
Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [7]
0
0
Time to Transformation acute myeloid leukemia (AML)
Query!
Assessment method [7]
0
0
Defined as blast count greater than or equal to 20% in either peripheral blood or bone marrow.
Query!
Timepoint [7]
0
0
Measured from the date of first dose of study drug to the date of documented AML transformation for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [8]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Measured from the date of the first dose of study drug to the date of earliest disease progression or death, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [9]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [9]
0
0
ORR (equals the sum of rates of complete remission [CR] + marrow complete remission (mCR) + partial remission [PR]) of venetoclax as a single-agent and in combination with azacitidine.
Query!
Timepoint [9]
0
0
Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [10]
0
0
Complete Remission (CR) Rate
Query!
Assessment method [10]
0
0
Proportion of subjects who achieved a complete remission.
Query!
Timepoint [10]
0
0
Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [11]
0
0
Rate of red blood cell (RBC) transfusion independence
Query!
Assessment method [11]
0
0
Proportion of red blood cell (RBC) transfusion independence.
Query!
Timepoint [11]
0
0
Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [12]
0
0
Duration of Complete Response (CR)
Query!
Assessment method [12]
0
0
Duration of CR will be defined as the number of days from the date of first response CR to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.
Query!
Timepoint [12]
0
0
Measured from date of first response (CR) to the to the earliest documentation of progressive disease or death of any cause, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [13]
0
0
Rate of Hematologic Improvement (HI)
Query!
Assessment method [13]
0
0
Proportion of participants with HI (erythroid/platelet/neutrophil responses)
Query!
Timepoint [13]
0
0
Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [14]
0
0
Rate of marrow complete remission (mCR)
Query!
Assessment method [14]
0
0
Proportion of participants with marrow complete remission with or without hematological improvement.
Query!
Timepoint [14]
0
0
Measured from Cycle 1 Day 1 (C1D1) as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Query!
Secondary outcome [15]
0
0
Duration of ORR
Query!
Assessment method [15]
0
0
Duration of response (ORR) will be defined as the number of days from the date of first response (CR or PR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.
Query!
Timepoint [15]
0
0
Measured from the date of first response (CR or PR) to the earliest documentation of progressive disease or death of any cause, and for an anticipated maximum duration of 24 months.
Query!
Eligibility
Key inclusion criteria
- Subjects who have relapsed or refractory MDS.
- Subject enrolled in venetoclax monotherapy must have documented failure of prior
therapy with a hypomethylating agent (HMA). HMA-failure is defined as:
1. Relapse after initial complete or partial response or hematological improvement
after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within
the last 5 years, OR
2. Failure to achieve complete or partial response or hematological improvement
after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within
the last 5 years
- Subjects must have presence of < 20% bone marrow blasts per bone marrow
biopsy/aspirate at screening.
- Subject is not a candidate to undergo allogenic hematopoietic stem cell
transplantation (HSCT).
- Subject must have an Eastern Cooperative Oncology Group (ECOG) performance score of
=2.
- Subject must have adequate hematologic, renal, and hepatic function.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subject has received prior therapy with a BH3 mimetic.
- Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).
- Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic
myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable
MDS/MPN.
- Subject has received allogeneic HSCT or solid organ transplantation.
- Subject has received a live attenuated vaccine within 4 weeks prior to the first dose
of study drug.
- Subject is pregnant or breastfeeding.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/03/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/04/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
70
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
St George Hospital /ID# 156037 - Kogarah
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital /ID# 155952 - Liverpool
Query!
Recruitment hospital [3]
0
0
St Vincent's Hospital Melbourne /ID# 155950 - Fitzroy Melbourne
Query!
Recruitment hospital [4]
0
0
The Royal Melbourne Hospital /ID# 155949 - Parkville
Query!
Recruitment hospital [5]
0
0
Royal Perth Hospital /ID# 155951 - Perth
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
3065 - Fitzroy Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [5]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Baden-Wuerttemberg
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Nordrhein-Westfalen
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Sachsen
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Dresden
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Halle (Saale)
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Munich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Celgene; Genentech, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and
pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in
participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02966782
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02966782
Download to PDF